<DOC>
	<DOCNO>NCT02962284</DOCNO>
	<brief_summary>This open-label , single-arm , multi-center extension study evaluate safety patient mCRPC YONSA 500 mg ( 4 x 125 mg qd ) methylprednisolone ( 4 mg bid ) . Patients successfully complete 84-day treatment abiraterone acetate previous trial . Results final visit previous study use determine patient 's eligibility study . Patients study eligible receive open-label YONSA methylprednisolone 12 month . Pharmacodynamic parameter serum testosterone PSA level monitor . Disease progression assess PCWG2 criterion .</brief_summary>
	<brief_title>One-year , Open Extension Evaluate Treatment Patients With Castration-Resistant Prostate Cancer With YONSAâ„¢</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Successful completion 84 day treatment YONSA Churchill Pharmaceuticals clinical trial , CHLAA201 Last dose YONSA Zytiga within 45 day prior treatment study Written inform consent obtain prior studyrelated procedure perform Has investigator 's opinion , potential gain clinical benefit YONSA treatment Ongoing therapy GnRH agonist antagonist AND serum testosterone level &lt; 50 ng/dL screen Life expectancy least 9 month screen Subject willing able comply protocol requirement assessment Agrees protocoldefined use effective contraception . Serious concurrent illness , include psychiatric illness , would interfere study participation Inability swallow tablet whole Known hypersensitivity YONSA , methylprednisolone , excipients study medication Moderate severe hepatic impairment ( ChildPugh Classes B C )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>